(Q84336201)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Vaccine discovery and translation of new vaccine technology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1

Rino Rappuoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Steven Black

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Paul Henri Lambert

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

12 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

378

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

9788

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

360-368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

Global Eradication of Smallpox

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Immunization against diphtheria with special emphasis on immunization of adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Rabies vaccine freed of the factor causing allergic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Vaccine policy changes and epidemiology of poliomyelitis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Impact of meningococcal C conjugate vaccine in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Reverse vaccinology, a genome-based approach to vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Post-genomic vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Principles of vaccine design-Lessons from nature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Systems biology: a brief overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

RNA vaccines in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Group A streptococcal infections and acute rheumatic fever

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Vaccination and autoimmune disease: what is the evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Molecular and cellular signatures of human vaccine adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Bacterial lipoproteins differentially regulate human primary and memory CD4+ T and B cell responses to pneumococcal protein antigens through Toll-like receptor 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Smallpox vaccination: a review, part II. Adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Pregnancy and H1N1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected childre

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

The next decade of vaccines: societal and scientific challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Multi-locus sequence typing: a tool for global epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Infectious disease. Costs of meningitis outbreaks are crippling, too.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960440-6

7 January 2021

10.1016/S0140-6736(11)60440-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664687%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference